40 studies found for:    Belimumab
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of Belimumab Administered Subcutaneously to Healthy Subjects
Condition: Healthy
Interventions: Biological: Single Dose Group: Belimumab IV 240 mg;   Biological: Single Dose Group: Belimumab SC 2 x 120 mg;   Biological: Single Dose Group: Belimumab SC 1 x 240 mg;   Biological: Single Dose Group: Belimumab SC 1 x 200 mg;   Biological: Multiple Dose Group: Belimumab SC 2 x 120 mg weekly;   Biological: Multiple Dose Group: Belimumab SC 1 x 200 mg weekly
2 Terminated Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant
Condition: Desensitization Before Kidney Transplant
Intervention: Drug: Belimumab
3 Terminated
Has Results
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab 100 mg SC
4 Completed
Has Results
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
5 Unknown  A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
Condition: Symptomatic Waldenstroms Macroglobulinaemia
Intervention: Drug: Belimumab
6 Recruiting A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Belimumab plus Early Vaccination;   Biological: Belimumab plus Late Vaccination
7 Completed
Has Results
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
8 Active, not recruiting A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Belimumab 1 mg/kg;   Biological: Belimumab 10 mg/kg
9 Completed Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: belimumab;   Biological: Placebo
10 Recruiting Belimumab in Remission of VASculitis
Condition: Vasculitis
Interventions: Biological: Placebo;   Biological: Belimumab 10 mg/kg;   Drug: Azathioprine
11 Recruiting Belimumab Assessment of Safety in SLE
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Other: Standard therapy
12 Recruiting Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
13 Active, not recruiting A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 200 mg SC plus standard therapy;   Drug: Standard therapy
14 Recruiting Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
15 Recruiting Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Condition: Systemic Lupus Erythematosus
Interventions: Biological: BENLYSTA;   Other: SLE treatment
16 Completed
Has Results
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 4 mg/kg;   Drug: Belimumab 10 mg/kg
17 Completed Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome
Condition: Sjögren's Syndrome
Intervention: Drug: Belimumab
18 Completed
Has Results
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 4 mg/kg;   Drug: Belimumab 10 mg/kg
19 Active, not recruiting Belimumab (BENLYSTA®) Pregnancy Registry
Condition: Systemic Lupus Erythematosus
Intervention: Drug: belimumab
20 Recruiting Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Belimumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years